MindWalk’s Q3 2026 revenue rose 52% year-over-year to $4.2 million, marking its third consecutive quarter of growth. Net loss from continuing operations narrowed to $3.9 million, while general and administrative expenses increased to $3.1 million, sales and marketing to $1.8 million, R&D to $1.2 million, and gross margin declined to 59%.

The company secured its first enterprise client on a recurring contract after successfully deploying its LensAI platform to solve complex drug discovery challenges. Management plans to roll out LensAI access to its full client base over the next 6–12 months, aiming to convert existing users into subscription revenues.

MindWalk remains in the preclinical stage, requiring substantial investment before any potential commercialization. Asset-level financing is structured to support independent, AI-driven programs through clinical readiness, with existing capital and in-house capabilities expected to keep development costs lower than traditional drug developers.